Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Deisseroth

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|February 3, 2007
Novel compounds with antiproliferative activity against imatinib-resistant cell linesEnrica I Lerma, Viet-Anh Nguyen, Tao Wang, et al.
Clinical Pharmacology and Therapeutics|February 3, 2018
Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer PatientsLiang Li, Lian Ma, Sarah J Schrieber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancerYucheng Tang, Hakan Akbulut, Jonathan Maynard, et al.
Investigative Ophthalmology & Visual Science|June 30, 2004
STAT3-mediated signaling in the determination of rod photoreceptor cell fate in mouse retinaSamuel Shao-Min Zhang, Jiye Wei, Hua Qin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNicole J Gormley, Chia-Wen Ko, Albert Deisseroth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2018
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual DiseaseEmily Y Jen, Qing Xu, Aaron Schetter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young AdultsRuo-Jing Li, Runyan Jin, Chao Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2015
FDA approval: siltuximab for the treatment of patients with multicentric Castleman diseaseAlbert Deisseroth, Chia-Wen Ko, Lei Nie, et al.
The Oncologist|February 12, 2020
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host DiseaseDonna Przepiorka, Lola Luo, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 MutationKelly J Norsworthy, Lola Luo, Vicky Hsu, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|February 3, 2007
Novel compounds with antiproliferative activity against imatinib-resistant cell linesEnrica I Lerma, Viet-Anh Nguyen, Tao Wang, et al.
Clinical Pharmacology and Therapeutics|February 3, 2018
Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer PatientsLiang Li, Lian Ma, Sarah J Schrieber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancerYucheng Tang, Hakan Akbulut, Jonathan Maynard, et al.
Investigative Ophthalmology & Visual Science|June 30, 2004
STAT3-mediated signaling in the determination of rod photoreceptor cell fate in mouse retinaSamuel Shao-Min Zhang, Jiye Wei, Hua Qin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2017
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaNicole J Gormley, Chia-Wen Ko, Albert Deisseroth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2018
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual DiseaseEmily Y Jen, Qing Xu, Aaron Schetter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young AdultsRuo-Jing Li, Runyan Jin, Chao Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2015
FDA approval: siltuximab for the treatment of patients with multicentric Castleman diseaseAlbert Deisseroth, Chia-Wen Ko, Lei Nie, et al.
The Oncologist|February 12, 2020
FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host DiseaseDonna Przepiorka, Lola Luo, Sriram Subramaniam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2019
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 MutationKelly J Norsworthy, Lola Luo, Vicky Hsu, et al.
Pageof 4